MedTrace Logo

DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects

NCT04086797 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2023-11-28

No results posted yet for this study

Summary

The main study objective is to evaluate the efficacy of IQP-AE-103 in reducing body weight in overweight and moderately obese subjects, in the context of an energy restricted diet. Further objectives are to evaluate the beneficial potential of IQP-AE-103 on waist circumference, blood pressure and blood glucose and lipid levels, quality of life, as well as its safety and tolerability

Conditions

Interventions

DIETARY_SUPPLEMENT

IQP-AE-103

1980 mg

DIETARY_SUPPLEMENT

Placebo

Placebo

Sponsors & Collaborators

  • Analyze & Realize

    collaborator NETWORK

  • Perrigo CSCI

    lead INDUSTRY

Principal Investigators

  • Ralf Uebelhack, MD · Analyze & Realize

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-11
Primary Completion
2021-04-08
Completion
2021-04-08

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04086797 on ClinicalTrials.gov